Bristol Myers Squibb (BMY) Income towards Parent Company (2009 - 2026)

Bristol Myers Squibb (BMY) posted quarterly Income towards Parent Company of $2.7 billion for Q1 2026, up 8.81% YoY from $2.5 billion in Q1 2025, and up 146.69% sequentially from $1.1 billion in Q4 2025.

Bristol Myers Squibb (BMY) Income towards Parent Company (2009 - 2026) Analysis & Trends

Bristol Myers Squibb has disclosed Income towards Parent Company across 18 years of filings, most recently posting $2.7 billion for Q1 2026.

  • In Q1 2026, Income towards Parent Company rose 8.81% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $7.3 billion (up 197.81% YoY), while the FY2025 annual figure was $7.1 billion, up 178.99% from the prior year.
  • Income towards Parent Company advanced to $2.7 billion in Q1 2026, from $1.1 billion in the prior quarter.
  • Over the last five years, Income towards Parent Company for BMY reached as high as $2.7 billion in Q1 2026 and fell as low as -$11.9 billion in Q1 2024.
  • The 5-year median for Income towards Parent Company is $1.6 billion (2024), against an average of $883.5 million.
  • Annual changes were most pronounced in 2024 — Income towards Parent Company tumbled 625.28% — and 2025, when it soared 1328.95%.
  • A 5-year view of Income towards Parent Company shows it stood at $2.0 billion in 2022, then fell by 15.7% to $1.7 billion in 2023, then slumped by 95.55% to $76.0 million in 2024, then soared by 1328.95% to $1.1 billion in 2025, then soared by 146.69% to $2.7 billion in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered $2.7 billion, $1.1 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Bristol Myers Squibb - - 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.68 Bn
Dec 31, 2025 1.09 Bn
Sep 30, 2025 2.20 Bn
Jun 30, 2025 1.31 Bn
Mar 31, 2025 2.46 Bn
Dec 31, 2024 76.00 Mn
Sep 30, 2024 1.16 Bn
Jun 30, 2024 1.63 Bn
Mar 31, 2024 -11.91 Bn
Dec 31, 2023 1.71 Bn
Sep 30, 2023 1.93 Bn
Jun 30, 2023 2.08 Bn
Mar 31, 2023 2.27 Bn
Dec 31, 2022 2.03 Bn
Sep 30, 2022 1.61 Bn
Jun 30, 2022 1.43 Bn
Mar 31, 2022 1.28 Bn
Dec 31, 2021 2.37 Bn
Sep 30, 2021 1.48 Bn
Jun 30, 2021 995.00 Mn